“CD20×CD3 Bispecific Antibodies in Relapsed Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety”. Journal of Medical Sciences 21, no. 2 (September 7, 2026): 30–35. Accessed September 24, 2026. https://sebhau.edu.ly/journal/joms/article/view/4892.